4Kadri Altundag, Ozden Altundag, Paolo Morandi, et al. CA125 Nadir Values As Prognostic Factor in Epithelial Ovarian Cancer [J]. J.Clin. Oncol,2005,23:2435-2436.
5Oliver Dorigo and Jonathan S, Berek. Personalizing CA125 Levels for Ovarian Cancer Screening [J]. Cancer Prevention Research,2011,4: 1356-1359.
6Jung Ha Shin, Jeong Hoon Bae, Ahwon Lee, et al. CK7,CK20,CDX2and MUC2 Immunohistochemical Staining Used To Distinguish Metastatic Colorectal Carcinoma Involving Ovary from Primary Ovarian Mucinous Adenocarcinoma [J]. J. Clin. Oncol,2010,40:208 - 213.
7Anna H.Woodard, Jing Yu, David J.Dabbs, et al. NY-BR-I and PAX8 Immunoreactivity in Breast,Gynecologic Tract, and Other CK7+ Carcinomas: Potential Use for Determining Site of Origin [J]. Am J Clin Pathol,2011,136:428-435.
8Marion T Weigel and Mitch Dowsett. Current and emerging biomarkers in breast cancer: prognosis and prediction [J]. Cancer, 2010,17:245 -262.
9Cynthia Kuk, Vathany Kulasingam, C.Geeth Gunawardana, et al. Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers[J]. Mol.Cell.Proteomics,2009,8:661-669.
10Ignacio Romero and Robert C. Bast, Jr.Minireview:Human Ovarian Cancer: Biology, Current Management,and Paths to Personalizing Therapy[J].Endocrinology,2012,153:1593 - 1602.
